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As many as 22% of people with type 2 diabetes could 
have vitamin B-12 deficiency.1 The cause of vitamin B-12 
deficiency in these patients remains controversial,2 but it 
can have important consequences and should be consid-
ered in the differential diagnosis of diabetic neuropathy. 
In small short term studies, treatment with metformin has 
been associated with reduced vitamin B-12 concentra-
tions and an increased risk of vitamin B-12 deficiency.3 4
Kooy and colleagues conducted a trial of the long term 
effects of metformin treatment on metabolic and micro-
vascular and macrovascular complications in patients 
with type 2 diabetes who were already taking insulin.5 
Three hundred and ninety patients were randomised to 
receive insulin plus metformin or insulin plus placebo. 
After a follow-up of 4.3 years, the study found fewer 
macrovascular events in the metformin group, which 
was largely accounted for by the beneficial effect of met-
formin on weight.
In the linked study this same group of authors, but with 
de Jager as first author, perform a further analysis of their 
earlier study and report important differences in serum 
vitamin B-12 in participants. In the placebo group, vitamin 
B-12 increased by 0.2 pmol/l (0%, 95% confidence inter-
val −3% to 4%), whereas in the group with the addition 
of metformin vitamin B-12 was reduced by 89.8 pmol/l 
(−19%, −22% to −15%). At baseline, three participants 
in the metformin group and four in the placebo group 
had vitamin B-12 concentrations below 150 pmol/l. At 
follow-up after 4.3 years this had increased to 19 and five 
participants, respectively. The reduction in concentra-
tions of vitamin B-12 in the metformin group persisted 
and become more apparent over time. The number needed 
to harm per 4.3 years was 13.8.6
Although the absolute number of affected participants 
was small the differences in vitamin B-12 concentrations 
are convincing. A strength of this study is the long period 
of follow-up.
The authors recommend that regular measurement 
of vitamin B-12 concentrations during long term met-
formin treatment should be considered. Sadly, though, 
they do not report on quality of life, neurological status, 
or measures of fatigue. Neither do they report whether 
participants received any dietary advice regarding vita-
min B-12. As their introduction makes clear, we have no 
robust research underpinning the assumption that people 
with vitamin B-12 concentrations of 150 pmol/l or less 
are indeed vitamin B-12 deficient. Although they may be 
at higher risk for vitamin B-12 deficiency related effects, 
these risks are not clearly quantified or always directly 
related to vitamin B-12 concentrations. An opportunity 
may have been missed to elucidate whether reduced vita-
min B-12 concentrations resulted in meaningful symp-
toms. Were the participants with lower concentrations of 
vitamin B-12 more likely to feel worse and have adverse 
effects?
Other uncertainties include whether or not these find-
ings apply to most patients managed in primary care, 
who are not usually treated with insulin—should these 
patients also be monitored for vitamin B-12 concentra-
tions? The conversion of patients with type 2 diabetes to 
insulin treatment is controversial,7 and it is the minority 
of patients whose diabetes is hardest to control who typi-
cally start insulin treatment. If patients are monitored, 
how should serum vitamin B-12 be measured?8 Further-
more, it is not clear what form the intervention should 
take. The options include dietary advice; increase intake 
of foods rich in calcium and vitamin B-12; and vita-
min B-12 supplements, which could be taken orally or 
injected9 10—most patients will not have problems absorb-
ing vitamin B-12 from the gut because this form of vitamin 
B-12 deficiency is unlikely to be related to intrinsic factor 
or bowel disease.
There are several other questions related to vitamin 
B-12 replacement. Given the long time it takes to deplete 
vitamin B-12 stores, how often—if at all—would intra-
muscular injections need to be repeated? Should con-
centrations be monitored once treatment is started? Can 
treatment be stopped after dietary improvement? Would 
we miss important morbidity by proceeding on the basis 
of symptoms and heightened clinical suspicion rather 
than on systematic screening in all patients taking met-
formin?
The case that de Jager and colleagues make for rou-
tine assessment of serum vitamin B-12 concentrations is 
based on findings from patients taking insulin and with 
no evidence that monitoring will benefit patients. The 
mechanisms are unclear, but it could be something as 
simple as the dietary change associated with metformin. 
We first need to determine whether simple dietary coun-
selling when metformin is started and at medication/
annual reviews will solve the problem. If it does not, a 
trial of screening for vitamin B-12 deficiency in patients 
taking metformin would be needed. Patients taking met-
formin (not just those also treated with insulin) should be 
randomised to systematic serum vitamin B-12 screening 
or routine care, with patient oriented outcomes and costs 
included in the outcomes. Otherwise, we risk increasing 
the burden on patients and the costs of care by treating 
biochemical outcomes rather than outcomes that matter 
to patients.
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Diagnosing diabetes using glycated haemoglobin A1c
Could have several advantages over traditional diagnostic methods
Diabetes is one of the three most prevalent chronic dis-
eases that pose serious threats to health. A recent study 
of 46 239 Chinese people aged 20 years or more indicated 
a prevalence of diabetes and prediabetes (blood glucose 
between normal and diabetic values) of 9.7% and 15.5%, 
respectively.1 These figures translate into a total of 92.4 
million people in China with diabetes. In the linked study, 
Bao and colleagues assess the value of glycated haemo-
globin A1c (HbA1c) in diagnosing diabetes and identify 
the optimal HbA1c cut-off value to be used in Chinese 
adults.2
Currently, fasting plasma glucose values and the oral glu-
cose tolerance test are most commonly used for the screen-
ing and diagnosis of diabetes. However, both require a fast 
of at least eight hours, and the oral glucose tolerance test 
also requires multiple blood collections, aspects that reduce 
patient compliance and limit their clinical application.
Recently HbA1c, a measure of long term glycaemic con-
trol, has been suggested as an alternative tool for diagnos-
ing diabetes. Because HbA1c values are proportional to the 
mean blood glucose concentration over the previous two 
to three months, patients do not need to fast, making these 
tests convenient and easy to perform.
In June 2009, an international expert committee consist-
ing of members from the American Diabetes Association, 
the European Association for the Study of Diabetes, and 
the International Diabetes Federation published a report 
recommending the use of an HbA1c value of 6.5% or more 
as a diagnostic criterion for diabetes.3 In the latest 2010 
version of Standards of Medical Care in Diabetes released 
by the American Diabetes Association,4 HbA1c values of 
6.5% or more and of 5.7% or more are recommended as 
diagnostic and screening criteria for diabetes, respectively. 
Similarly, a recent community based study assessing the 
validity of HbA1c for the diagnosis of diabetes in Asian 
Indians proposed that HbA1c thresholds of 6.1% and 6.5% 
could be used as screening and diagnostic tests for diabetes, 
respectively.5 Previous studies have shown, however, that 
the optimal cut-off point of HbA1c for detecting diabetes may 
vary by racial or ethnic group.6 7
Little information regarding the usefulness of HbA1c tests 
in the diagnosis of diabetes is available for Chinese popu-
lations. In the linked cross sectional survey Bao and col-
leagues assess the usefulness of HbA1c as a screening and 
diagnostic tool for diabetes compared with fasting plasma 
glucose concentrations and the oral glucose tolerance test 
in 4900 Chinese adults with no history of diabetes.2 Their 
results suggest that for those at high risk for diabetes, an 
HbA1c cut-off value of 6.3% or more had a significantly 
higher sensitivity than fasting plasma glucose at 7.0 mmol/l 
or more and of the generally suggested HbA1c threshold 
of 6.5% or more. HbA1c therefore provides an alternative 
method for screening and diagnosing diabetes in the clini-
cal setting. Furthermore, HbA1c can be sampled at any time, 
improving patient compliance and enabling timely diag-
nosis of people who do not meet the criteria for fasting and 
those who are unwilling to take the oral glucose tolerance 
test.
Currently, most general hospitals in China can carry out 
HbA1c tests. In addition, the Chinese Ministry of Health is 
implementing a quality control system for HbA1c tests. The 
study by Bao and colleagues established an optimal HbA1c 
cut-off value of 6.3% or more as a diagnostic criterion for 
diabetes in Chinese adults. Nevertheless, further epidemio-
logical and clinical studies on a larger scale, particularly 
prospective ones, are needed to validate the efficacy of 
HbA1c for diagnosing diabetes, and to tackle the association 
of HbA1c diagnostic cut-off points with chronic complica-
tions of diabetes, such as retinopathy.
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hIV transmission in serodiscordant heterosexual couples
risk is not zero but is low if the infected partner takes antiretrovirals 
Antiretroviral treatment inhibits HIV viral replication 
and reduces plasma viral load. Low plasma viral load is 
associated with a lower probability of HIV transmission, 
which opens the possibility of treatment to reduce HIV 
transmission.1 2 The feasibility, potential effectiveness, 
and risks of such treatment are unclear, and a key uncer-
tainty is the extent to which successful antiretroviral treat-
ment reduces HIV infectivity. In the linked observational 
study, Del Romero and colleagues estimate the risk of 
heterosexual transmission of HIV-1 from infected people 
taking combined antiretroviral treatment.3 
Only randomised controlled trials comparing transmis-
sion in HIV serodiscordant couples, where the infected 
(index) partner receives or does not receive antiretroviral 
drugs, can accurately estimate the effect of such treatment 
on infectivity. The HPTN-052 trial is the only ongoing trial 
of this type. In this trial, partners infected with HIV are 
assigned to immediate antiretroviral treatment or deferred 
treatment when their CD4 count drops below 250 cells/μl. 
This trial will hopefully provide a good estimate of the effect 
of antiretroviral treatment in patients with more than 250 
CD4 cells/μl, but it will obviously not obtain an estimate in 
patients with fewer than 250 CD4 cells/μl.
Evidence that antiretroviral treatment reduces sexual 
transmission of HIV comes from observational studies 
of serodiscordant couples and ecological studies,2 4 5 but 
transmission from patients on antiretroviral treatment 
has also been documented.6 Del Romero and colleagues’ 
study is a welcome addition to the observational studies 
that estimate infectivity in serodiscordant couples. In 
partners of patients with HIV not receiving treatment, the 
incidence of HIV was 0.6 per 100 couple years, whereas 
none of the partners of patients on antiretroviral treat-
ment seroconverted. The authors also computed the prob-
ability of transmission per unprotected sex act (figure). 
The infectivity estimates were low and imprecise, with 
no significant difference between treated and untreated 
patients (figs 1 and 2, see bmj.com). The authors there-
fore conclude that transmission of HIV from successfully 
treated patients cannot be excluded, because it is bio-
logically possible and because the data are consistent 
with one infection per 91 couple years (compared with 
one per 71 couple years in untreated couples). Moreover, 
because this is an observational study, the treated and 
non-treated groups are most probably not comparable. 
Patients receiving treatment are necessarily different 
because of their poorer clinical history. Some differences 
were also seen in risk behaviour and characteristics of 
the index partners at baseline and during follow-up, 
which may have increased transmission in couples with 
an untreated index partner.3
How do the results of Del Romero’s study compare with 
other studies? Apart from four studies from high income 
countries conducted before the era of antiretroviral treat-
ment that also reported no seroconversion, the infectiv-
ity estimates in the non-treated group were generally 
lower in Del Romero’s study than in previous studies.4 7 8 
A recent systematic review of observational studies in 
heterosexual serodiscordant couples found five studies 
reporting HIV infectivity estimates according to treat-
ment. In two of these studies with information on viral 
load, no seroconversions were seen when treated index 
patients had viral loads of fewer than 400 copies/ml. One 
study from Uganda reported no seroconversions in part-
ners of treated cases despite only 79% having achieved 
a viral load fewer than 400 copies/ml six months after 
the start of treatment. A more recent study (not in the 
systematic review4) in seven African countries observed 
one seroconversion in 256 person years of follow-up in 
partners of index cases.9
Together, these seven studies of patients receiving 
antiretroviral treatment independently of viral load 
will help to provide a more precise overall estimate of 
the seroconversion rate.3 4 9 Although the probability of 
transmission during antiretroviral treatment seems to 
be greater than zero, these studies support the idea that 
treatment reduces infectivity, which could translate into 
benefits at the population level, as long as risk behaviour 
does not increase. To date, some studies,5 but not all,10 
suggest a beneficial effect of antiretroviral treatment at 
the community level.
What effect do these data have on counselling serodis-
cordant couples? In 2008, the Swiss Federal AIDS Com-
mission released a controversial statement to the effect 
that HIV infected people with undetectable concentra-
tions of the virus (<40 copies/ml) for at least six months, 
who adhered to a strict antiretroviral drug programme 
and had no other sexually transmitted infections, were 
not infectious to their regular heterosexual partners.11 
The challenge for counsellors is to ensure that people 
understand the exact set of conditions and time period 
when it seems to be safe to have unprotected sex. Del 
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Transmission risk per sex act
-0.001 0 0.001 0.002 0.003 0.004 0.005
Del Romero et al 2010
  ART, mono-bitherapy, C
  ART, combined treatment, C
  With condoms, C
  No ART, C
  All couples, C
Boily et al 2009
  C, high income countries (n=4)
  FM, high income countries (n=3)
  MF, high income countries (n=10)
  FM, low income countries (n=5)
  MF, low income countries (n=7)
Per sex act heterosexual transmission probability estimates 
with and without antiretroviral treatment (ART)3 compared 
with pooled estimates before the ART era.7 n=number of 
studies included in pooled estimates; FM=female to male, 
MF=male to female; C=MF and FM combined
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Romero and colleagues are more cautious and continue 
to promote the use of condoms regardless of viral load; 
in their study condom use reduced HIV transmission by 
93%.
On the basis of current evidence, we conclude that 
although taking antiretroviral treatment reduces the risks 
of vaginal intercourse with an HIV positive partner, inter-
course is not totally risk free. Despite their limitations, 
additional studies in discordant couples are needed to 
estimate the infection risk more precisely, especially for 
homosexual and heterosexual anal intercourse.7 12 It is 
unclear how these results for heterosexual populations 
will translate to homosexuals.
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In November 2009, the National Institute for Health and 
Clinical Excellence (NICE) published guidance for employ-
ers on promoting mental wellbeing through productive 
and healthy working conditions.1 Excess work related 
stress harms employees’ physical and mental health. 
From an economic perspective, impaired efficiency at work 
associated with mental health problems costs the United 
Kingdom £15.1bn (€16.9bn; $22.5bn) a year.2 From a 
health perspective, stress at work is consistently associ-
ated with increased total mortality and acute myocardial 
infarction.3 4
Ideally, the guidelines should outline discrete steps 
that could easily be implemented, improve the efficiency 
and satisfaction of workers, and ultimately be shown in 
a randomised controlled trial to improve morbidity and 
mortality. Although the guidance falls short of this ideal, 
business managers and human resources departments may 
still benefit from the advice.
Unfortunately, some of the advice is so general that it is 
almost useless. For example, the first recommendation in 
the guidance is to: “Adopt an organisation-wide approach 
to promoting the mental wellbeing of all employees, work-
ing in partnership with them. This approach should inte-
grate the promotion of mental wellbeing into all policies 
and practices concerned with managing people, including 
those related to employment rights and working condi-
tions.” This reads more like a mission statement than a 
discrete step that a responsible business manager could 
implement. Other recommendations are more practical, 
however; examples of how to monitor mental wellbeing 
(such as attitude or satisfaction surveys, and data on 
absence rates and employee turnover) are reasonable and 
appropriate for different sized businesses. Other advice, 
such as allowing workers flexible hours, and that man-
agers “respond with sensitivity to employees’ emotional 
concerns” may seem to lag behind policies already in place 
in many human resource departments.
Perhaps the lack of concrete guidance comes from the 
diverse and changing nature of stress. Stress is not easy 
to measure—after all, it is subjective. The NICE guidance 
defines stress as “the adverse reaction people have to exces-
sive pressure or other types of demand placed on them,” 
meaning that, by definition, workplace stress is excessive. 
Other major causes of chronic disease—physical  inactivity, 
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smoking, poor nutrition, and excessive alcohol use—are 
at least quantifiable, so it is easier to study the effects of 
sp ecific interventions.5
Physical inactivity can be measured using a pedometer, 
which can be provided to each employee with encour-
agement to walk for 30 minutes every day. Smoking can 
be measured by cotinine concentrations and banned on 
premises, and there could be a ban on hiring smokers 
(allowable in 39 US states). Unhealthy eating and obes-
ity can be monitored through body mass index, waist size, 
and portion sizes. People can be advised to eat five serv-
ings of fruits and vegetables a day, and the organisation can 
help them do this by making healthy food available and 
unhealthy food less so. Alcohol intake can be quantified.
Evidence shows that programmes to manage stress in the 
workplace have beneficial effects. Much of the best work 
in this field comes from Japan, where workplace stress is 
high—more than 60% of Japanese workers report high lev-
els of anxiety and stress.6 Two recent randomised controlled 
trials showed that single session educational programmes 
for supervisors, compared with no programme, can signifi-
cantly improve knowledge,7 reduce psychological distress in 
workers, and improve job performance.6 8 One programme 
that taught stress management in hospitals decreased the 
frequency of malpractice claims (arguably a proxy in the 
United States for preventable medical errors) in 22 hospitals 
by 71% compared with a 3% decrease in hospitals without 
a stress management programme.9 Such a programme also 
decreased physician (and nurse) burnout and improved 
physician (and nurse) satisfaction with work.10 11
The NICE guidance implies that the difficulty in meas-
uring stress should not deter organisations from trying to 
reduce it. Organisations will be more successful if employ-
ers help their workers to manage stress.9
The science of reducing stress in the workplace is in its 
infancy, and completing the circle from business policies 
to improved clinical outcomes is far away. In the meantime, 
the NICE guidelines can provide some basic advice for busi-
nesses wishing to make an impact on productivity and their 
employees’ health.
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Acupuncture, which is based on the theory that inserting 
and manipulating fine needles at specific acupuncture 
points located in a network of meridians will promote the 
harmonious flow of “Qi,” is one of the most widely prac-
tised modalities of alternative medicine. Because needles 
are inserted up to several centimetres beneath the skin, 
acupuncture may pose risks to patients. One of the most 
important complications is transmission of pathogenic 
micro-organisms, from environment to patient or from one 
patient to another.
In the 1970s and 1980s most infections associated with 
acupuncture were sporadic cases involving pyogenic bac-
teria.1 So far, more than 50 cases have been described glo-
bally. In most cases, pyogenic bacteria were transmitted 
from the patient’s skin flora or the environment because of 
inadequate skin disinfection before acupuncture. In local-
ised infections, meridian specific and acupuncture point 
specific lesions were typical. About 70% of patients had 
musculoskeletal or skin infections, usually in the form of 
abscesses or septic arthritis, corresponding to the site of 
insertion of the acupuncture needles.1 2 A minority had 
infective endocarditis, meningitis, endophthalmitis, cervi-
cal spondylitis, retroperitoneal abscess, intra-abdominal 
abscess, or thoracic empyema.3 4
As in other musculoskeletal or skin infections, 
 Staphylococcus aureus was the most common bacterium 
responsible, accounting for more than half of the reported 
cases.1 2 Although most patients recovered, 5-10% died 
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of the infections and at least another 10% had serious 
co nsequences such as joint destruction, paraplegia, 
necrotising fasciitis, and multiorgan failure.1 2
Apart from pyogenic bacterial infections, five outbreaks 
of hepatitis B virus infection associated with acupunc-
ture, which affected more than 80 patients, have been 
described globally since the 1970s.5 6 In most outbreaks 
the sources were infected patients, and the virus was 
transmitted from one patient to another through improp-
erly sterilised or unsterilised reusable acupuncture 
n eedles, but in one outbreak an acupuncturist who was 
positive for hepatitis B surface antigen and hepatitis B e 
antigen was thought to be the source.5 6
The other two major bloodborne viruses, hepatitis 
C virus and HIV, could hypothetically be transmitted 
by acupuncture. Most evidence for the association of 
he patitis C virus infection with acupuncture came from 
epidemiological and case-control studies, where acu-
puncture was found to be an independent risk factor for 
hepatitis C virus infections.7 Although no clear evidence 
exists to support a link between acupuncture and HIV 
infection, there are reports of patients with HIV who had 
no risk factors other than acupuncture.8
A new clinical syndrome has emerged in the 21st cen-
tury—acupuncture mycobacteriosis—which is mainly 
caused by rapidly growing mycobacteria.9 These myco-
bacteria are thought to be transmitted from the environ-
ment to patients via contaminated equipment used in 
acupuncture, such as cottonwool swabs, towels, hot pack 
covers, and boiling tanks. All mycobacterial infections 
associated with acupuncture so far have been character-
ised by localised meridian specific and acupuncture point 
specific lesions without dissemination.9 10 The lesions 
usually first appear as erythematous papules and nodules 
that subsequently develop into large pustules, abscesses, 
and ulcerative lesions after several weeks to months. 
Patients tended to delay seeking medical advice because 
of the slowly developing and relatively mild symptoms. 
Owing to the relatively hardy nature of mycobacteria,10 
the long incubation period of the infection, and the dif-
ficulty in making a diagnosis, mycobacteria have caused 
two large outbreaks associated with acupuncture, which 
affected more than 70 patients.11 12
The case reports and outbreaks of acupuncture trans-
mitted infections may be the tip of the iceberg. The first 
reports of meticillin resistant S aureus (MRSA) transmit-
ted by acupuncture appeared in 2009.2 The emergence of 
community associated MRSA infections may aggravate the 
problem. To prevent infections transmitted by acupunc-
ture, infection control measures should be implemented, 
such as use of disposable needles, skin disinfection pro-
cedures, and aseptic techniques. Stricter regulation and 
accreditation requirements are also needed.
Clinicians should also have a high index of suspicion, 
particularly for viral and mycobacterial infections trans-
mitted by acupuncture because of their prolonged incu-
bation periods, and they should alert health authorities 
about clusters of cases.
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standards to single use, sterile needles.” Steven mavros, president, Association for Professional Acupuncture, PA, USA
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